...
首页> 外文期刊>Immunology Letters >Increased Th17 cells and interleukin-17 contribute to immune activation and disease aggravation in patients with chronic hepatitis B virus infection
【24h】

Increased Th17 cells and interleukin-17 contribute to immune activation and disease aggravation in patients with chronic hepatitis B virus infection

机译:慢性乙型肝炎病毒感染患者中Th17细胞和白介素17的增加有助于免疫激活和疾病加重

获取原文
获取原文并翻译 | 示例
           

摘要

T helper17 (Th17) cells have been demonstrated to participate in the pathogenesis of hepatitis B virus (HBV) associated liver damage. However, the contribution of Th17 cells to immune activation and disease aggravation in patients with HBV infection is not fully clear. In this study, we investigated the Th17 cells frequencies and interleukin-17 (IL-17) mRNA expressions in peripheral blood mononuclear cells (PBMCs), intrahepatic IL-17-positive cells accumulation, as well as serum IL-17 levels in asymptomatic chronic HBV carriers (AsC), and patients with chronic hepatitis B (CHB) and HBV related acute-on-chronic liver failure (ACLF). Furthermore, the dynamic changes of Th17 cells frequencies and IL-17 concentration in different prognostic ACLF patients were observed. As result, the intrahepatic and peripheral Th17 cells and serum IL-17 concentration were both significantly higher in CHB and HBV related ACLF patients than that in AsC and normal control groups, and increased gradually with immune inflammation aggravation from AsC, CHB to ACLF. Moreover, in ACLF patients, peripheral Th17 cells frequencies were positively correlated with international normalized ratio (INR) and model of end-stage liver disease (MELD) score. Especially the survival patients had an initially lower Th17 cells frequencies and IL-17 levels which gradually decreased following condition improvement as compared with higher baseline level followed by gradually increasing trend in the non-survivals. In conclusion, Th17 cells can be contributed to the immune activation and disease aggravation in patients with chronic HBV infection. This may places Th17 cells as a potential blocking target for controlling CHB and ACLF. ? 2012 Elsevier B.V.
机译:T辅助细胞(Th17)已被证明参与乙型肝炎病毒(HBV)相关肝损伤的发病机制。然而,对于HBV感染患者,Th17细胞对免疫激活和疾病加重的贡献尚不清楚。在这项研究中,我们调查了无症状慢性患者外周血单核细胞(PBMC)中Th17细胞的频率和白细胞介素17(IL-17)mRNA的表达,肝内IL-17阳性细胞的积累以及血清IL-17的水平。 HBV携带者(AsC),以及慢性乙型肝炎(CHB)和HBV相关的急性慢性肝功能衰竭(ACLF)患者。此外,观察了不同预后的ACLF患者Th17细胞频率和IL-17浓度的动态变化。结果,CHB和HBV相关ACLF患者的肝内和外周血Th17细胞和血清IL-17浓度均显着高于AsC组和正常对照组,并随着AsC,CHB至ACLF的免疫炎症加重而逐渐升高。此外,在ACLF患者中,外周血Th17细胞频率与国际标准化比率(INR)和晚期肝病模型(MELD)得分呈正相关。特别是存活的患者最初具有较低的Th17细胞频率和IL-17水平,与较高的基线水平相比,随着条件的改善,其逐渐降低,随后非存活者的趋势逐渐升高。总之,Th17细胞可以促进慢性HBV感染患者的免疫激活和疾病加重。这可能会将Th17细胞作为控制CHB和ACLF的潜在阻断靶标。 ? 2012年Elsevier B.V.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号